Zoth Lota S. — SEC Form 4 filings
SEC reporting owner CIK 1278219. 14 Form 4 filings on record with FilingPulse; latest filed 2026-06-17.
Transaction summary — filings shown
Covers all 14 filings on record, filed 2024-02-05 to 2026-06-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 30.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| LUMOS PHARMA, INC. | Director | 2 | — | — | 9 |
| 89bio, Inc. (ETNB) | Director | 3 | — | — | 8 |
| INOVIO PHARMACEUTICALS, INC. (INO) | Director | 4 | — | — | 8 |
| enGene Therapeutics Inc. (ENGN) | Director | 4 | — | — | 4 |
| FIRST FINANCIAL BANKSHARES INC (FFIN) | Director | 1 | — | — | 1 |
Form 4 filings — Zoth Lota S.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-17 | 4 | enGene Therapeutics Inc. (ENGN) | Grant/award (A): 31,000 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | INOVIO PHARMACEUTICALS, INC. (INO) | Grant/award (A): 41,800 (derivative) @ $0 · Grant/award (A): 34,200 (derivative) @ $0 | EDGAR |
| 2026-05-05 | 4 | FIRST FINANCIAL BANKSHARES INC (FFIN) | Grant/award (A): 2,142 @ $0 | EDGAR |
| 2025-10-30 | 4 | 89bio, Inc. (ETNB) | Disposition to issuer (D): 20,000 (derivative) @ $0 · Disposition to issuer (D): 12,500 (derivative) @ $0 · Disposition to issuer (D): 25,000 (derivative) @ $0 · Disposition to issuer (D): 27,400 (derivative) @ $0 · Disposition to issuer (D): 45,150 (derivative) @ $0 · Disposition to issuer (D): 56,400 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | enGene Holdings Inc. (ENGN) | Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | INOVIO PHARMACEUTICALS, INC. (INO) | Option exercise (M): 2,167 · Option exercise (M): 2,167 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | 89bio, Inc. (ETNB) | Grant/award (A): 56,400 (derivative) @ $0 | EDGAR |
| 2024-12-13 | 4 | LUMOS PHARMA, INC. | Disposition to issuer (D): 2,187 · Disposition to issuer (D): 3,345 (derivative) · Disposition to issuer (D): 3,328 (derivative) · Disposition to issuer (D): 5,684 (derivative) · Disposition to issuer (D): 3,431 (derivative) · Disposition to issuer (D): 2,910 (derivative) · +2 more | EDGAR |
| 2024-06-18 | 4 | enGene Holdings Inc. (ENGN) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | LUMOS PHARMA, INC. | Grant/award (A): 3,328 (derivative) @ $0 | EDGAR |
| 2024-05-22 | 4 | INOVIO PHARMACEUTICALS, INC. (INO) | Grant/award (A): 2,917 (derivative) @ $0 · Grant/award (A): 2,167 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | INOVIO PHARMACEUTICALS, INC. (INO) | Option exercise (M): 2,166 · Option exercise (M): 2,166 (derivative) @ $0 | EDGAR |
| 2024-03-25 | 4 | enGene Holdings Inc. (ENGN) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | 89bio, Inc. (ETNB) | Grant/award (A): 45,150 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1278219 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →